Market Overview

Epistem Announces a Three Year Collaboration with GlaxoSmithKline in Fibrosis Research


Epistem announces a three year biomarker collaboration with GlaxoSmithKline (NYSE: GSK) in the field of fibrosis research. The collaboration will focus on identifying key characteristics of diseased fibrotic tissue on which Epistem will apply its proprietary RNA-Amp™ technology to facilitate building an in depth understanding of the disease.

Posted-In: News Contracts


Related Articles (GSK)

View Comments and Join the Discussion!

Get Benzinga's Newsletters